Observational studyEuropean urology2026

Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study.

Elizabeth K Bancroft et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.